Condition: Prostate Cancer · Metastatic Castration Resistant Prostate Cancer · Metastatic Castration-sensitive Prostate Cancer · Sponsor: Astellas Pharma Global Development, Inc.
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without another medicine called enzalutamide. * to check if the men can tolerate PRL-02 depot given with or without enzalutamide. * to find a suitable dose of PRL-02 depot. This study will be in 2 parts. In the first part, different small groups of men will receive lower to higher doses of PRL-02 depot together with other medicines. In the second part of the study, men who have previously taken a hormone therapy called abiraterone acetate or have previously taken 1 specific hormone therapy as part of their prostate cancer treatment can take part. Men in both parts of the study will receive injections of PRL-02 depot into a muscle once every 12 weeks. They will also take dexamethasone or prednisone, or enzalutamide once a day. The other medicines they take depend on which group and which part of the study they are in. During the study, the men will visit the clinic several times for health checks and scans. After the final visit, men whose cancer has not become worse will continue to have…
This description comes directly from the study's public registry record.
Astellas Pharma Global Development, Inc. · 800-888-7704 · Astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| Arizona Urology Specialists | Tucson, Arizona, United States | Withdrawn |
| Los Angeles Cancer Network | Anaheim, California, United States | Recruiting |
| Providence Medical Group Oncology Santa Rosa | Santa Rosa, California, United States | Recruiting |
| Florida Urology Partners | Tampa, Florida, United States | Withdrawn |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne, Indiana, United States | Withdrawn |
| First Urology | Jeffersonville, Indiana, United States | Recruiting |
| Wichita Urology Group | Wichita, Kansas, United States | Recruiting |
| National Cancer Institute | Bethesda, Maryland, United States | Withdrawn |
| Chesapeake Urology | Towson, Maryland, United States | Recruiting |
| XCancer Center Omaha/Urology Cancer Center | Omaha, Nebraska, United States | Completed |
| Garden Sate Urology | Morristown, New Jersey, United States | Withdrawn |
| New Mexico Oncology Hematology Consultants Ltd | Albuquerque, New Mexico, United States | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04729114